Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”

Greene et al. raw datasets. by Justin Greene (306625)

Multiple bacterial subpopulations are present within splenic microcolonies. by Justin Greene (306625)

Droplet-based microfluidics can be used to model clustered bacterial growth. by Justin Greene (306625)

Acceptance of the HPV vaccine. by Mohammad Delwer Hossain Hawlader (11558838)

“…The vaccine acceptance level was positively associated with all the domains of the HBM (p<0.001), except in the perceived barrier domain (p = 0.489). …”

Cues to the action question. by Mohammad Delwer Hossain Hawlader (11558838)

“…The vaccine acceptance level was positively associated with all the domains of the HBM (p<0.001), except in the perceived barrier domain (p = 0.489). …”

Characteristics of the respondents (n = 2,151). by Mohammad Delwer Hossain Hawlader (11558838)

“…The vaccine acceptance level was positively associated with all the domains of the HBM (p<0.001), except in the perceived barrier domain (p = 0.489). …”

Determinants of HPV vaccine acceptance. by Mohammad Delwer Hossain Hawlader (11558838)

“…The vaccine acceptance level was positively associated with all the domains of the HBM (p<0.001), except in the perceived barrier domain (p = 0.489). …”

Quantification of single cell areas during MgOx treatment. by Justin Greene (306625)

MgOx treatment is not sufficient to alter S10 reporter activity. by Justin Greene (306625)

ROC Results Predicted in the Sample. by Fangyi Yang (18867853)

“…The model estimation results indicate that passenger patience significantly influences drop-off decisions. All models—static, dynamic, and Cox proportional hazards—achieved prediction accuracies exceeding 70%, with the dynamic model outperforming others when ample sample data is available. …”

ROC Results Predicted for Out of the Sample. by Fangyi Yang (18867853)

“…The model estimation results indicate that passenger patience significantly influences drop-off decisions. All models—static, dynamic, and Cox proportional hazards—achieved prediction accuracies exceeding 70%, with the dynamic model outperforming others when ample sample data is available. …”

Lack of T3SS expression was associated with lower S10 expression. by Justin Greene (306625)

T3SS induction slows growth, but cells can support high levels of S10 expression. by Justin Greene (306625)

Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 3_Association between platelet-to-red cell distribution width ratio and all-cause mortality in critically ill patients with non-traumatic cerebral hemorrhage: a retrospective... by Rongrong Lu (322302)

“…As PRR increased, restrictive cubic splines showed a progressive decrease in the probability of all-cause mortality. …”